Our findings that both BCL2L1 and MAPK1 are co‐expressed in key biological pathways related to drug resistance, apoptosis and PIK3‐AKT signaling are in agreement with other studies in both NSCLC and other cancer types [27, 37, 38, 39, 40]. This evidence concerns the gene BCL2L1 and non-small cell lung carcinoma.